EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and ABBVIE S.À.R.L. Dated as of September 20, 2013Exclusive License Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 2nd, 2017 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) is made and entered into effective as of September 20, 2013 (the “Effective Date”) by and between Ablynx NV, a company organized under the laws of Belgium, having its principal place of business at Technologiepark 21, B-9052 Ghent—Zwijnaarde, Belgium (“Ablynx”), and AbbVie S.à.r.l., a corporation organized under the laws of Luxembourg and having a principal place of business at 26 Boulevard Royal; L-2449 Luxembourg (“AbbVie”). Ablynx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and ABBVIE S.À.R.L. Dated as of September 20, 2013Exclusive License Agreement • August 30th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 30th, 2017 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) is made and entered into effective as of September 20, 2013 (the “Effective Date”) by and between Ablynx NV, a company organized under the laws of Belgium, having its principal place of business at Technologiepark 21, B-9052 Ghent—Zwijnaarde, Belgium (“Ablynx”), and AbbVie S.à.r.l., a corporation organized under the laws of Luxembourg and having a principal place of business at 26 Boulevard Royal; L-2449 Luxembourg (“AbbVie”). Ablynx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”